Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.

Leukotriene B4 (LTB4) is a potent, proinflammatory lipid mediator implicated in the pathologies of an array of inflammatory diseases and cancer. The biosynthesis of LTB4 is regulated by the leukotriene A4 hydrolase (LTAH). Compounds capable of limiting the formation of LTB4, through selective inhibition of LTAH, are expected to provide potent anti-inflammatory and anti-cancer agents. The aim of the current study is to obtain potential LTAH inhibitors using computer-aided drug design. A hybrid 3D structure-based pharmacophore model was generated based on the crystal structure of LTAH in complex with bestatin. The generated pharmacophore was used in a virtual screen of the Maybridge database. The retrieved hits were extensively filtered, then docked into the active site of the enzyme. Finally, they were consensually scored to yield five hits as potential LTAH inhibitors. Consequently, the selected hits were purchased and their biological activity assessed in vitro against the epoxide hydrolase activity of LTAH. The results were very promising, with the most active compound showing 73.6% inhibition of the basal epoxide hydrolase activity of LTAH. The results from this exploratory study provide valuable information for the design and development of more potent and selective inhibitors.